# G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

> **NCT00253552** · NA · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 4 (actual)

## Conditions studied

- Chronic Myeloproliferative Disorders
- Graft Versus Host Disease
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Diseases
- Sarcoma

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** busulfan
- **DRUG:** cyclophosphamide
- **DRUG:** cyclosporine
- **DRUG:** etoposide
- **DRUG:** methotrexate
- **PROCEDURE:** allogeneic bone marrow transplantation
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00253552
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-05
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Terminated at request of PI as study was outdated.
- **Last updated:** 2012-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00253552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00253552, "G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00253552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*